Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma in Situ 2Virus Diseases 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urinary Bladder Diseases 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Adenoviridae Infections 1

Interventions

apaziquone 4Mitomycin 3viscum album peptide 1valrubicin 1pembrolizumab 1linrodostat 1enzalutamide 1enfortumab vedotin 1avelumab 1Sugars 1Standard of Care 1Polysorbates 1Pentosan Sulfuric Polyester 1Nivolumab 1Gemcitabine 1DDMS 1Capsules 1Bevacizumab 1ALT-801 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Non-Muscle Invasive Bladder Neoplasms × valrubicin × Clear all
NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals

Phase 3 Terminated
1 enrolled 5 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡